Filter     Order  Title asc Title desc Ordering    Display #  5 10 15 20 25 30 50 Item Title Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway Debiopharm and Aurigene enter into an Agreement to identify and develop selective compounds for immuno-oncology targets   < Prev 1 Next > Results 1 - 2 of 2

Tremelimumab - codevelopment with Pfizer Inc  ( 1 items ) Debio 0931  ( 1 items ) Debio 0932  ( 2 items ) Debio 0930  ( 1 items ) Debio 0929  ( 1 items ) Debio 0928  ( 1 items ) Debio 0827  ( 1 items ) Debio 0826  ( 1 items ) Triptorelin – Trelstar® – Decapeptyl® - Pamorelin®  ( 14 items ) Debio 8609 Sanvar®  ( 13 items ) Debio 025  ( 9 items ) Debio 9902 - ZT-1  ( 9 items ) Debio 0614 (istaroxime)  ( 2 items ) Debio 0507  ( 3 items ) Debio 0719  ( 1 items ) Oxaliplatin – Eloxatin® – Elplat®  ( 10 items ) Moapar® - Salvacyl®  ( 5 items ) Other News  ( 55 items )